 Sofosbuvir
"Sofosbuvir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.
| Descriptor ID |
D000069474
|
| MeSH Number(s) |
D03.383.742.686.850.877.500 D13.695.740.850.877.500 D13.695.827.919.877.500
|
| Concept/Terms |
Sofosbuvir- Sofosbuvir
- 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester
PSI 7977- PSI 7977
- 7977, PSI
- PSI7977
- PSI-7977
|
Below are MeSH descriptors whose meaning is more general than "Sofosbuvir".
Below are MeSH descriptors whose meaning is more specific than "Sofosbuvir".
This graph shows the total number of publications written about "Sofosbuvir" by people in this website by year, and whether "Sofosbuvir" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 5 | 4 | 9 | | 2016 | 4 | 1 | 5 | | 2017 | 6 | 2 | 8 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 3 | 4 | | 2020 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 0 | 1 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Sofosbuvir" by people in Profiles.
-
Chappell CA, Kiser JJ, Brooks KM, Randolph R, Macio IS, Meyn LA, MaWhinney S, Rick AM, Muniz GB, Kwon KM, Letterio C, Naik S, Kreter B, Bunge KE, Krans EE, Hillier SL. Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clin Infect Dis. 2025 Apr 30; 80(4):744-751.
-
Jonas MM, Romero R, Rosenthal P, Lin CH, Verucchi G, Wen J, Balistreri WF, Whitworth S, Bansal S, Leung DH, Narkewicz MR, Gonzalez-Peralta RP, Mangia A, Karnsakul W, Rao GS, Shao J, de Jong J, Parhy B, Osinusi A, Kersey K, Murray KF, Sokal EM, Schwarz KB. Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
-
Steinbrink JM, Narayanasamy S, Wolfe CR, Maziarz E, Byrns J, Kiser JJ, Naggie S. Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases. Am J Kidney Dis. 2023 09; 82(3):368-372.
-
Brooks KM, Castillo-Mancilla JR, Morrow M, Mawhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah L, Tehrani A, Jimmerson LC, Roon L, Bushman LR, Anderson PL, Kiser JJ. Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use. J Antimicrob Chemother. 2022 04 27; 77(5):1396-1403.
-
Bricker-Ford R, Brumenschenkel A. Case Report of Hepatitis C Treatment Success in Male With Decompensated Cirrhosis and Polysubstance Abuse: The Important Role of the Pharmacist in Active Care Coordination. J Pharm Pract. 2023 Jun; 36(3):725-727.
-
Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-Bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022 04; 7(4):307-317.
-
Terrault NA, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, Victor D, Mohan S, Trotter J, Dodge J, Niemann CU, Rubin RA. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology. 2021 06; 73(6):2110-2123.
-
Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Blum J, Wyles DL, Rowan SE, Ibrahim ME, Zheng JH, Johnson B, Gomez J, Choi YJ, Cendali F, Haas H, Roon L, Bushman LR, Anderson PL, Kiser JJ. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother. 2020 11 01; 75(11):3303-3310.
-
Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, Mittal N, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Narkewicz MR, Rao GS, Whitworth S, Bansal S, Balistreri WF. Ledipasvir-Sofosbuvir for 12?Weeks in Children 3 to <6?Years Old With Chronic Hepatitis C. Hepatology. 2020 02; 71(2):422-430.
-
Brooks KM, Castillo-Mancilla JR, Blum J, Huntley R, MaWhinney S, Alexander K, Kerr BJ, Ellison L, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. J Antimicrob Chemother. 2019 08 01; 74(8):2360-2364.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|